25Jul/13

Biogen Idec Delivers Double-Digit Top & Bottom-Line Growth in Second Quarter … – DailyFinance

Biogen Idec Delivers Double-Digit Top & Bottom-Line Growth in Second Quarter
DailyFinance
We estimate that approximately $82 million of TECFIDERA revenues in the second quarter represent inventory in the channel while revenue generated from underlying patient demand was approximately $110 million. RITUXAN® (rituximab) revenues from 
Biogen Idec Inc (BIIB) Management Discusses Q2 2013 Results – Earnings Call Seeking Alpha

all 30 news articles »

25Jul/13

Biogen Idec Delivers Double-Digit Top & Bottom-Line Growth in Second Quarter … – MarketWatch

Biogen Idec Delivers Double-Digit Top & Bottom-Line Growth in Second Quarter
MarketWatch
RITUXAN(R) (rituximab) revenues from our unconsolidated joint business arrangement were $289 million for the quarter, an increase of 1% compared to the second quarter of 2012. “With a strong start for TECFIDERA in the U.S., as well as approvals in 
Biogen Idec Inc (BIIB) Management Discusses Q2 2013 Results – Earnings Call Seeking Alpha

all 27 news articles »